NEW YORK, Sept. 16, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continue

Analysts raised targets for RAPP, ALLR, UNP and ALVO; cut targets for NU, CLLS and JBHT, with severa

Wells Fargo analyst Derek Archila maintains Disc Medicine (NASDAQ:IRON) with a Overweight and rai

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,

Disc Medicine, Inc. (IRON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Trans

NEW YORK, Sept. 12, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,

NEW YORK, Sept. 11, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continue

Disc Medicine says Phase 2 RESTORE-PV data shows DISC-3405 reduces phlebotomy needs and controls hem

Wedbush analyst David Nierengarten reiterates Disc Medicine (NASDAQ:IRON) with a Outperform and m

WATERTOWN, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-s

NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,

New York, New York--(Newsfile Corp. - September 8, 2026) - WHY: Rosen Law Firm, a global investor ri

XPENG has officially commissioned its humanoid robot production lines and completed the production-l

NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,

New York, New York--(Newsfile Corp. - September 2, 2026) - WHY: Rosen Law Firm, a global investor ri

Wedbush analyst David Nierengarten maintains Disc Medicine (NASDAQ:IRON) with a Outperform and ra

WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-s

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Inv

NEW YORK, Aug. 31, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, cont

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discove

WATERTOWN, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-st

NEW YORK, Aug. 29, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,

Disc Medicine, Inc. (NASDAQ: IRON - Get Free Report) has been assigned an average recommendation of

NEW YORK, Aug. 26, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues

NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,

HC Wainwright & Co. analyst Douglas Tsao maintains Disc Medicine (NASDAQ:IRON) with a Buy and

Disc Medicine (NASDAQ:IRON) reported quarterly losses of $(1.54) per share which beat the analyst co

Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 168.2% to $7.94 during Friday&

Morgan Stanley analyst Sean Laaman maintains Disc Medicine (NASDAQ:IRON) with a Overweight and ra

Wedbush analyst David Nierengarten reiterates Disc Medicine (NASDAQ:IRON) with a Outperform and m

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discove

Consistent, substantial decreases in hepcidin reaching >75% reduction from baseline and correspon

Morgan Stanley analyst Sean Laaman maintains Disc Medicine (NASDAQ:IRON) with a Overweight and ra

https://subscriber.politicopro.com/article/2026/05/makarys-time-atop-fda-over-tktk-named-acting-comm

https://www.cbsnews.com/news/trump-approves-plan-to-fire-fda-commissioner-marty-makary/?intcid=CNM-0

Disc Medicine (NASDAQ:IRON) reported quarterly losses of $(1.65) per share which beat the analyst co

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discove

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discove

Wells Fargo analyst Derek Archila maintains Disc Medicine (NASDAQ:IRON) with a Overweight and rai

On February 26, 2026, the board of directors of Disc Medicine, Inc. (the "Company") approved

Truist Securities analyst Danielle Brill maintains Disc Medicine (NASDAQ:IRON) with a Buy and low

Disc Medicine (NASDAQ:IRON) reported quarterly losses of $(1.62) per share which beat the analyst co

Stifel analyst Stephen Willey maintains Disc Medicine (NASDAQ:IRON) with a Buy and lowers the pri

Cantor Fitzgerald analyst Kristen Kluska maintains Disc Medicine (NASDAQ:IRON) with a Overweight

BMO Capital analyst Evan David Seigerman maintains Disc Medicine (NASDAQ:IRON) with a Outperform

Wedbush analyst David Nierengarten maintains Disc Medicine (NASDAQ:IRON) with a Outperform and lo

Wells Fargo analyst Derek Archila maintains Disc Medicine (NASDAQ:IRON) with a Overweight and low

Disc Medicine stock plunged after an FDA rejection of its rare disease drug but rebounded as investo

Disc Medicine, Inc. (NASDAQ:IRON), a biopharmaceutical company focused on the discovery, development